Navigation Links
Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
Date:8/6/2009

s its programs under development; and the expected receipt of clinical trial data from Genentech in the second half of 2010 and the expected shareholder and corporate benefits of any advancement of clinical trials of GDC-0449;. Forward-looking statements used in this press release may contain the words "believes", "expects", "anticipates", "plans", "seeks", "estimates", "will", "may" or similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other important factors that may cause the actual results to be materially different from those indicated by such forward-looking statements including, among other things:

    - Curis may experience adverse results, delays and/or failures
      in its internal drug development programs, including with respect to
      its phase I clinical trial of CUDC-101, and with respect to its ongoing
      preclinical studies of its other targeted cancer programs.
    - Genentech and Debiopharm may experience adverse results, delays
      and/or failures in their strategic alliance transactions with Curis.
      For example, Genentech may not be able to replicate in later trials any
      favourable outcomes from earlier trials of GDC-0449, and Debiopharm may
      not be able to successfully advance CUDC-305 into clinical trials as
      planned.
    - Curis may experience difficulties or delays in obtaining or
      maintaining required regulatory approvals for products under
      development both internally and through its collaborations.
    - Curis may not be able to obtain or maintain the intellectual
      property protection necessary for the development and commercialization
      of drug candidates based on its technologies.
    - Curis may not be able to obtain the substantial additional
      funding required to conduct research and development of its drug
      candidates.
    - Curis may experien
'/>"/>
SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
2. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
3. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
4. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
5. Japanese Cancer Association and Debiopharm Honour Japanese Research
6. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
7. Debiopharm and EPFL Establish an Oncology Chair
8. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
9. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
10. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
11. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 ... of Trendlines Agtech , announced it has ... Israel,s leading agricultural thermoplastics applications companies. ... Valentis,s technology combines nanocrystalline cellulose (NCC), a biodegradable, ... additional nanoparticles to produce highly improved polymeric films. ...
(Date:7/23/2014)... MOINES, Iowa (PRWEB) July 23, 2014 ... join the business as vice president of Agricultural Biotechnology ... Mendel Biotechnology where he served most recently as president, ... extensive biotechnology and business leadership in the seed and ... Pioneer,” said Paul E. Schickler , president of ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire/ - BioAmber ... biotechnology company producing sustainable chemicals, today announced that the ... full their option to purchase an additional 420,000 ... price of $12.00 per share, less underwriting discounts ... underwritten public offering of 2,800,000 shares of common ...
(Date:7/23/2014)... regulated information -- UCB today announced an ... with positive topline results from the latest Phase ... designed to evaluate the efficacy and safety of ... titration) compared to placebo, as adjunctive treatment in ... fully controlled despite treatment with one or two ...
Breaking Biology Technology:Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7
... April 9, 2012 The University of Southern California Marshall ... announced its 6th Annual Marshall School of Business Leadership ... 11:00 am to 5:30 pm, at Los Angeles, newest landmark, ... (Logo: http://photos.prnewswire.com/prnh/20120409/LA84249LOGO ) A new dynamic ...
... WALTHAM, Mass., April 9, 2012   Syndax Pharmaceuticals, ... that investigators at The University of Texas MD ... have initiated a phase 1/2 study combining Syndax,s ... patients with locally recurrent or distant relapsed metastatic ...
... Carbon Limited today announces that they will be exhibiting at ... sheet of carbon just one atom thick, has been described ... University in 2004, for which the team was awarded a ... commercially. To support this work the UK Government recently ...
Cached Biology Technology:USC Marshall School of Business 6th Annual Leadership Summit 2USC Marshall School of Business 6th Annual Leadership Summit 3Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer 2Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer 3UK company to demonstrate their commercially effective graphene production process 2
(Date:7/23/2014)... blood-brain barrier damage appear after cerebral infarction, ... metalloproteinase-9 is able to degrade the major ... blood vessels and to mediate extracellular matrix ... from the First Affiliated Hospital of Medical ... cerebral infarction in stroke-prone spontaneously hypertensive rats ...
(Date:7/23/2014)... Neuroprotection by ischemic preconditioning has been confirmed by ... In a study released in the Neural ... Dr. Yong Liu and co-workers from Tongji Hospital ... Science and Technology, China performed cerebral ischemic preconditioning ... and explored the mechanism underlying the neuroprotective effect ...
(Date:7/23/2014)... region of the brain is important for ... the underlying mechanisms are unclear. Dr. Zhouyan ... monitored the activity of hippocampal neurons in ... mechanisms underlying the neuronal responses. Somatosensory stimulation, ... local field potentials into theta rhythm-dominated waveforms, ...
Breaking Biology News(10 mins):
... Department of Health Policy and Management at Columbia,s ... of pollution on agricultural worker productivity using daily ... ozone, even at levels below current air-quality standards ... negative impacts on worker productivity. Their findings suggest ...
... Department of Energy,s National Renewable Energy Laboratory (NREL) will ... in a five-year, $7 million effort to economically produce ... feedstocks, the federal laboratory announced today. The work ... Agreement (CRADA) between NREL and Johnson Matthey. "It,s ...
... Scientists at The University of Manchester have used synchrotron-based imaging ... Their work on a 50 million year old lizard ... demonstrating for the first time that this fossil animal was ... using some of the brightest light in the universe, x-rays ...
Cached Biology News:Ozone levels have sizeable impact on worker productivity 2NREL and Johnson Matthey announce 5-year collaboration on biofuels 2Prehistoric ghosts revealing new details 2
... P20 plus,for Reliable Sterile Filtration of Tissue ... a,membrane pump or tube pump, quickly and,reliably ... media,and aqueous solutions. The combination of ... automatic de-aeration,ensures high flow rates and optimal ...
... fluorescent microscopy-based imaging system that accurately counts ... calculates cell viability, in a single test. ... variability associated with the subjective interpretation of ... EasyCount ViaSure Kit, up to six tests ...
... The new Adept CE 4100 high ... superb flow precision, with software drive compensation, ... from 0.001-10mL/min are selectable in 0.001mL steps. ... are inert and bio-compatible., Pumps may be ...
... membrane and filter paper sandwiches are composed ... two sheets of thick filter paper that ... filter paper sandwich. These 7 x 8.5 ... immunoblotting fit Ready Gel-sized gels and are ...
Biology Products: